Stockhub

Viking Therapeutics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

21 August 2022

14 August 2022

31 July 2022

  • curprev 16:4716:47, 31 July 2022‎ Chris talk contribs‎ 941 bytes +941‎ Created page with "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally a..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Viking_Therapeutics,_Inc.’